Abbott Laboratories’ financial results were negatively impacted by a sharp drop in COVID-19 test sales in Q1. The company’s market-beating dividend is well covered. The stock’s valuation ...

Abbott Labs has a long and successful track record of innovation, significant experience in navigating the healthcare industry, and has generally produced excellent returns for long-term investors.

Sales growth in the medical devices segment drove Abbott Laboratories’ expectations-beating revenue in the past financial quarter as the company faces lower demand for COVID-19 tests, it ...

Baby formula issues and a decline in COVID-19 test sales continue to hamper Abbott Laboratories as the company now faces a U.S. Justice Department investigation.